Latest Ratios: P/E Ratio 13.8x · EV/EBITDA 9.9x · ROE 20.3%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.2B | $1.8B | $1.1B | $764M | $1.3B | $2.4B | $2.1B | $2.3B | $3.0B | $5.0B | $6.2B |
| Enterprise Value | $2.5B | $2.1B | $1.5B | $1.4B | $2.0B | $3.0B | $2.8B | $4.0B | $5.0B | $6.8B | $7.9B |
| P/E Ratio → | 13.84 | 11.03 | — | — | 18.81 | 17.90 | — | — | 11.26 | 15.63 | 19.21 |
| P/S Ratio | 1.17 | 0.95 | 0.54 | 0.38 | 0.63 | 1.23 | 1.21 | 1.32 | 0.83 | 1.45 | 1.96 |
| P/B Ratio | 2.64 | 2.11 | 1.43 | 0.90 | 1.40 | 2.62 | 2.81 | 1.56 | 0.98 | 1.63 | 2.26 |
| P/FCF | 8.83 | 7.22 | 5.92 | 7.35 | 9.11 | 52.86 | 11.95 | 6.92 | 12.54 | 10.84 | 15.44 |
| P/OCF | 8.23 | 6.73 | 5.29 | 5.57 | 7.49 | 30.64 | 10.27 | 6.55 | 10.43 | 9.79 | 14.08 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.10 | 0.76 | 0.70 | 0.99 | 1.59 | 1.60 | 2.26 | 1.36 | 1.97 | 2.48 |
| EV / EBITDA | 9.95 | 8.34 | — | 32.03 | 9.40 | 12.89 | 21.97 | 20.37 | 9.37 | 11.67 | 11.95 |
| EV / EBIT | 10.89 | 8.36 | — | — | 16.17 | 14.86 | 23.64 | 22.66 | 11.18 | 14.78 | 13.81 |
| EV / FCF | — | 8.35 | 8.27 | 13.39 | 14.26 | 68.11 | 15.82 | 11.90 | 20.58 | 14.72 | 19.52 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 24.7% | 24.7% | 22.6% | 21.1% | 23.7% | 26.9% | 25.9% | 28.3% | 27.1% | 28.9% | 32.5% |
| Operating Margin | 12.1% | 12.1% | -3.4% | 0.4% | 8.8% | 10.6% | 5.7% | 9.7% | 12.2% | 13.9% | 18.0% |
| Net Profit Margin | 8.6% | 8.6% | -4.9% | -3.0% | 3.4% | 6.9% | -45.9% | -84.2% | 7.4% | 9.3% | 10.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.3% | 20.3% | -12.3% | -6.9% | 7.4% | 15.9% | -70.9% | -65.3% | 8.7% | 11.0% | 12.5% |
| ROA | 7.5% | 7.5% | -4.5% | -2.6% | 2.6% | 4.3% | -21.3% | -29.7% | 4.6% | 5.7% | 6.6% |
| ROIC | 14.8% | 14.8% | -3.9% | 0.4% | 8.2% | 10.1% | 3.2% | 3.1% | 6.8% | 7.8% | 10.6% |
| ROCE | 13.2% | 13.2% | -3.9% | 0.4% | 8.2% | 7.8% | 3.0% | 3.8% | 8.2% | 9.3% | 12.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.76 | 0.76 | 0.87 | 0.83 | 0.80 | 1.19 | 2.41 | 1.20 | 0.64 | 0.60 | 0.62 |
| Debt / EBITDA | 2.61 | 2.61 | — | 16.13 | 3.44 | 4.53 | 14.26 | 9.07 | 3.73 | 3.18 | 2.58 |
| Net Debt / Equity | — | 0.33 | 0.57 | 0.74 | 0.79 | 0.76 | 0.91 | 1.12 | 0.63 | 0.58 | 0.60 |
| Net Debt / EBITDA | 1.13 | 1.13 | — | 14.45 | 3.39 | 2.89 | 5.38 | 8.52 | 3.66 | 3.08 | 2.50 |
| Debt / FCF | — | 1.13 | 2.34 | 6.04 | 5.15 | 15.25 | 3.87 | 4.98 | 8.04 | 3.88 | 4.08 |
| Interest Coverage | 7.02 | 7.02 | -1.49 | -0.15 | 3.05 | 2.97 | 1.06 | 1.49 | 4.78 | 6.17 | 9.06 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.66 | 1.66 | 1.47 | 1.24 | 1.00 | 1.97 | 3.49 | 1.35 | 1.40 | 1.43 | 1.44 |
| Quick Ratio | 1.66 | 1.66 | 1.47 | 1.24 | 1.00 | 1.97 | 3.49 | 1.35 | 1.40 | 1.43 | 1.44 |
| Cash Ratio | 1.09 | 1.09 | 0.80 | 0.46 | 0.24 | 1.14 | 2.77 | 0.34 | 0.13 | 0.16 | 0.16 |
| Asset Turnover | — | 0.85 | 0.94 | 0.90 | 0.84 | 0.70 | 0.52 | 0.43 | 0.61 | 0.59 | 0.60 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 46.21 | 49.43 | 51.22 | 54.93 | 60.35 | 50.93 | 89.06 | 50.71 | 53.19 | 56.79 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 7.2% | 9.1% | — | — | 5.3% | 5.6% | — | — | 8.9% | 6.4% | 5.2% |
| FCF Yield | 11.3% | 13.9% | 16.9% | 13.6% | 11.0% | 1.9% | 8.4% | 14.5% | 8.0% | 9.2% | 6.5% |
| Buyback Yield | 3.9% | 4.8% | 0.2% | 0.1% | 7.1% | 0.2% | 0.4% | 6.2% | 10.0% | 1.4% | 1.0% |
| Total Shareholder Yield | 3.9% | 4.8% | 0.2% | 0.1% | 7.1% | 0.2% | 0.4% | 6.2% | 10.0% | 1.4% | 1.0% |
| Shares Outstanding | — | $85M | $83M | $82M | $84M | $86M | $86M | $84M | $92M | $94M | $94M |
Regulatory Reimbursement Compression
As reported in recent financial data, Pediatrix trades at a P/E of 12.72 and an EV/EBITDA of 9.23, suggesting that investors are pricing in significant uncertainty regarding the company's ability to stabilize margins following its strategic pivot away from non-core medical specialties and recent revenue contraction.
The current valuation multiples appear to reflect a 'show-me' narrative where the market is discounting the company's potential for organic growth due to the secular headwinds in birth rates. Investors should monitor whether the forward P/E of 10.81 represents a value opportunity or a trap, given that the lack of a clear PEG ratio indicates an absence of consensus on future earnings expansion.
Based on quarterly filings, the company's ROIC has struggled to maintain positive momentum, fluctuating between a low of -7.9% in 2024Q2 and a peak of 4.2% in 2025Q3, which indicates that the firm is currently failing to consistently generate returns above its cost of capital.
The erratic ROIC trend suggests that the company's capital allocation, particularly regarding past acquisitions, has not yet yielded the expected synergies. The persistent reliance on goodwill, which remains a significant portion of the asset base, implies that future returns on capital may remain suppressed unless management can successfully drive organic growth in its core neonatal business.
According to the provided financial statements, the company's asset turnover remains stagnant at approximately 0.22, while DSO levels hovering around 45 to 52 days highlight persistent challenges in revenue cycle management and the collection of payments from third-party payers in a complex regulatory environment.
The lack of improvement in asset turnover suggests that the company is not effectively leveraging its existing infrastructure to generate higher revenue per dollar of assets. This inefficiency, combined with the volatility in DSO, warrants further investigation into whether the company's billing processes are adequately adapting to the requirements of the No Surprises Act.
As evidenced by the company's financial reports, the debt-to-equity ratio has trended downward from 0.99 in 2024Q2 to 0.72 in 2026Q1, signaling a disciplined approach to balance sheet management that provides a necessary buffer against the inherent volatility of the healthcare services sector.
While the reduction in leverage is a positive signal for long-term solvency, the interest coverage ratio remains highly sensitive to operating income swings, as seen in the 2024Q2 period. Investors should monitor whether this conservative leverage profile is maintained as the company navigates potential future M&A to offset organic volume declines.
The market frequently misapplies the U.S. birth rate as the primary proxy for Pediatrix's revenue growth, which obscures the more critical driver of NICU acuity and the company's ability to capture higher-margin, complex cases that are less sensitive to raw demographic trends.
Relying solely on birth rate statistics ignores the structural shift toward higher-acuity care, which is the actual engine of the company's revenue. Analysts should instead focus on the 'Average Daily Census' and 'Payer Mix' metrics, as these provide a more accurate assessment of the company's earning power than broad macroeconomic demographic data.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MD stock.
Pediatrix Medical Group, Inc.'s current P/E ratio is 13.8x. The historical average is 26.3x. This places it at the 15th percentile of its historical range.
Pediatrix Medical Group, Inc.'s current EV/EBITDA is 9.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.0x.
Pediatrix Medical Group, Inc.'s return on equity (ROE) is 20.3%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 6.5%.
Based on historical data, Pediatrix Medical Group, Inc. is trading at a P/E of 13.8x. This is at the 15th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Pediatrix Medical Group, Inc. has 24.7% gross margin and 12.1% operating margin. Operating margin between 10-20% is typical for established companies.
Pediatrix Medical Group, Inc.'s Debt/EBITDA ratio is 2.6x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.